Overall Survival

In DESTINY-Breast03, a head-to-head study vs T-DM1,

Overall survival was analyzed but immature at time of data cutoff (May 21, 2021)1,2,a

Secondary endpoint: Overall survival

Kaplan-Meier curve depicting immature overall survival for ENHERTU and T-DM1. Kaplan-Meier curve depicting immature overall survival for ENHERTU and T-DM1.

ENHERTU (n=261) T-DM1 (n=263)
mOS, months (95% CI) NE (NE, NE) NE (NE, NE)
12-month OS rate, % (95% CI) 94.1 (90.3, 96.4) 85.9 (80.9, 89.7)
HR (95% CI) 0.55 (0.36, 0.86)

aAt the time of the PFS analysis, 16% of patients had died.

Downloadable Resource for You:

    Take a closer look at the DESTINY-Breast03
    efficacy and safety data

CI, confidence interval; HR, hazard ratio; mOS, median overall survival; NE, not evaluable; OS, overall survival; T-DM1, ado-trastuzumab emtansine.